Claims for Patent: 10,556,008

Summary for Patent: 10,556,008

Title:	Methods of treatment of keloid using an anti-VEGF agent
Abstract:	Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
Inventor(s):	Pham; Randal Tanh Hoang (San Jose, CA)
Assignee:
Application Number:	15/700,992
Patent Claims:	1. A method for treating keloid recurrence, the method comprising administering a therapeutically effective amount of (1) an anti-VEGF antibody, (2) an anti-inflammatory steroid, and (3) a non-steroidal anti-inflammatory drug (NSAID) to a site where a keloid has been removed from a subject, wherein the anti-inflammatory steroid is alclometasone, diflorasone, fluocinonide, or prednicarbate, and the NSAID is diclofenac. 2. The method of claim 1, wherein the anti-VEGF antibody is the antibody bevacizumab. 3. The method according to claim 2, wherein the bevacizumab is administered at a dose of 10 mg. 4. The method of claim 1, wherein the anti-VEGF antibody is administered by injection or topically. 5. The method of claim 4, wherein the anti-VEGF antibody is injected at or adjacent to a site of new blood vessel growth at the site of keloid removal. 6. The method of claim 1, wherein the anti-inflammatory steroid is applied topically, systemically, or by injection to the site of keloid removal. 7. The method of claim 1, further comprising administering to the site one or more subsequent administrations of one or more of an anti-VEGF antibody, an anti-inflammatory steroid, and an NSAID. 8. The method of claim 1, further comprising administering NSAID or steroid eye drops to the site where a keloid has been removed from a subject; said administration of eye drops occurring before the administration of the anti-VEGF antibody. 9. The method of claim 8, wherein the administration of the anti-VEGF antibody, the anti-inflammatory steroid, and the NSAID are performed according to a regimen selected from the group consisting of: a) Day 1: Steroid eye drops and NSAID eye drops applied to eye; Day 34: Bevacizumab and Kenalog.RTM. injected into eye; Day 6: Bevacizumab injected into eye; and Day 20: Bevacizumab injected into eye; b) Day 1: Steroid eye drops applied to eye; Day 34: Bevacizumab and Kenalog.RTM. injected into eye; Day 47: NSAID eye drops applied to eye; Day 78: Bevacizumab injected into eye; Day 90: Bevacizumab injected into eye; c) Day 1: Steroid eye drops applied to eye; Day 8: Bevacizumab injected into right eye; Day 9: NSAID eye drops applied to eye; Day 28: Bevacizumab injected into eye; d) Day 14: NSAID eye drops applied to eye; Day 15: Bevacizumab and Kenalog.RTM. injected into eye; Day 32: Bevacizumab injected into eye; Day 47: Bevacizumab and Kenalog.RTM. injected into eye; and Day 231: Bevacizumab injected into eye; wherein the Day refers to the number of days after a surgical removal and conjunctival grafting procedure on the eye. 10. The method of claim 9, wherein the regimen occurs after a first, a second, or a third surgical removal of a pterygium and conjunctival grafting procedure. 11. The method of claim 1, wherein the anti-inflammatory steroid is alclometasone 0.005% cream, diflorasone 0.005% cream, fluocinonide cream 0.1%, or prednicarbate topical 0.1% cream; and the NSAID is diclofenac 0.1%. 12. The method of claim 1, wherein anti-inflammatory steroid drops are administered for up to 6 weeks with a frequency range from every hour to once a day, and wherein NSAID eye drops are administered for 3 to 6 months multiple times a day.

Details for Patent 10,556,008

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-12-28